VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

November 08, 2010 10:46 ET

VentriPoint Diagnostics Ltd. Retains The Howard Group for Investor Relations

SEATTLE, WASHINGTON--(Marketwire - Nov. 8, 2010) - VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT), a company focused on better diagnostic imaging for all heart diseases, announced today that, subject to regulatory approval, it has entered into an Investor Relations agreement ("IR Agreement") with The Howard Group Inc. ("HGI") of Calgary, Alberta, to provide investor relation services and to develop and implement a capital markets program. Traditional and new online initiatives will be directed at the investment community and investing public to increase the following and market participation in VentriPoint. VentriPoint has started selling its diagnostic systems to hospitals and its investor awareness program is being developed to support this.

Since 1988, HGI has provided comprehensive investor and capital markets programs, business development solutions, strategic planning and financing services to public companies. HGI is associated with the Insight Limited Partnerships I & II, which invest in micro and small cap companies.

The IR Agreement is for a term of 12 months and may be extended by mutual agreement until October 31, 2012. HGI shall be paid $7,000 per month provided that HGI shall only be paid $3,500 per month until the Corporation receives additional funding exceeding $2,000,000 (the "Funding"). Once the Funding is received by the Corporation, HGI will be paid the arrears outstanding and future monthly payments shall be for the full $7,000 monthly fee. In addition to the monthly fee, HGI has been granted an option to purchase 150,000 common shares at an exercise price of $0.22 per share for a period of five years and will be granted an additional option to purchase 200,000 shares at the prevailing market price once the Funding is completed, subject to the policies and approval of the TSX Venture Exchange.

For further information on The Howard Group Inc., please visit In addition to its ongoing investor relations services, The Howard Group Inc. will be providing an ongoing commentary on VentriPoint's activities in its free, online live newsletter, INSIGHT. Interested parties are encouraged to subscribe to the newsletter feed by emailing below with the subject line, VentriPoint:

About VentriPoint Diagnostics Ltd. VentriPoint creates diagnostic systems to monitor patients with heart disease, the number one cause of death in developed countries. The VMS is the first cost-effective and accurate diagnostic tool for measuring right ventricle heart function. Congenital heart disease is the first application with additional applications in process to enable monitoring of all major heart diseases including pulmonary hypertension, cardiovascular disease and heart failure - a $10 Billion market potential. Canada and Europe (CE Mark) have granted approval for the sale of its VMS diagnostic tool and a 510(k) submission is currently being reviewed by the U.S. Federal Drug Administration. For further information about VentriPoint go to

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information